

Alexander J F Lazar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5456451/alexander-j-f-lazar-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

418
papers

34,747
citations

87
h-index

177
g-index

458
ext. papers

46,948
ext. citations

10.5
avg, IF

6.58
L-index

#	Paper	IF	Citations
418	NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.. <i>Pathology and Oncology Research</i> , 2022 , 28, 1610237	2.6	0
417	Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients.. <i>Oncotarget</i> , 2022 , 13, 521-533	3.3	0
416	Multi-site desmoplastic small round cell tumors are genetically related and immune-cold.. <i>Npj Precision Oncology</i> , 2022 , 6, 21	9.8	1
415	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.. <i>Cancer Cell</i> , 2022 , 40, 509-523.e6	24.3	10
414	Pigmented PRRX1::NCOA1-rearranged Fibroblastic Tumor: A Rare Morphologic Variant of an Emerging Mesenchymal Tumor.. <i>Journal of Cutaneous Pathology</i> , 2022 ,	1.7	
413	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , 2021 , 374, 1632-1640	33.3	52
412	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	9
411	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. <i>Onc Immunology</i> , 2021 , 10, 1992880 ²	7.2	2
410	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. <i>Cancer</i> , 2021 , 127, 2666-2673	6.4	2
409	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. <i>JAMA Network Open</i> , 2021 , 4, e210945	10.4	10
408	Synovial Sarcoma of the Hand and Foot: An Institutional Review. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 361-368	2.7	0
407	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. <i>Scientific Reports</i> , 2021 , 11, 9362	4.9	3
406	Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. <i>Npj Genomic Medicine</i> , 2021 , 6, 30	6.2	1
405	A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. <i>Journal of Pathology</i> , 2021 , 254, 109-120	9.4	2
404	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441	50.5	57
403	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1597-1605	6.7	3
402	Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. <i>Cancer Cytopathology</i> , 2021 , 129, 374-382 ⁹	3.9	8

401	Radiation-associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation. <i>Histopathology</i> , 2021 , 78, 321-326	7.3	10
400	Diagnosis of digestive system tumours. <i>International Journal of Cancer</i> , 2021 , 148, 1040-1050	7.5	10
399	INSM1 Expression in Angiosarcoma. <i>American Journal of Clinical Pathology</i> , 2021 , 155, 575-580	1.9	3
398	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskelatal Ewing Sarcoma. <i>Oncologist</i> , 2021 , 26, 250-260	5.7	5
397	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021 , 148, 560-571	7.5	9
396	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. <i>Cell Reports</i> , 2021 , 34, 108678	10.6	7
395	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. <i>Frontiers in Oncology</i> , 2021 , 11, 631766	5.3	1
394	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. <i>Acta Neuropathologica</i> , 2021 , 142, 565-590	14.3	0
393	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. <i>Cell Reports</i> , 2021 , 36, 109410	10.6	2
392	Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 842-850	5	
391	Analytical protocol to identify local ancestry-associated molecular features in cancer. <i>STAR Protocols</i> , 2021 , 2, 100766	1.4	0
390	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdaa177	0.9	4
389	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , 2021 , 27, 141-151	50.5	30
388	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.. <i>Cancer Discovery</i> , 2021 ,	24.4	5
387	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020 , 6, 16	7.8	47
386	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
385	The Long Noncoding RNA Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways. <i>Molecular Cancer Research</i> , 2020 , 18, 1534-1544	6.6	4
384	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1165-1172	6.1	9

383	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020 , 250, 667-684	9.4	83
382	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020 , 12,	6.6	10
381	Soft Tissue 2020 , 229-283		
380	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020 , 11, 1008	17.4	77
379	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020 , 577, 556-560	50.4	538
378	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
377	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1429-1441	2.2	9
376	Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. <i>Cancer</i> , 2020 , 126, 3265-3273	6.4	9
375	AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors 2020 , 4, 511-525		
374	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. <i>Cancer Cell</i> , 2020 , 37, 639-654.e6	24.3	56
373	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. <i>Cell Reports</i> , 2020 , 33, 108293	10.6	7
372	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020 , 9, 8650-8661	4.8	3
371	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy 2020 , 8,		14
370	Tumors of neuroectodermal origin 2020 , 437-538		
369	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020 , 33, 496-513	9.8	9
368	Skeletal Muscle Tumors 2020 , 283-296		
367	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. <i>Journal of Pathology: Clinical Research</i> , 2020 , 6, 195-206	5.3	17
366	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020 , 11, 1839	17.4	9

365	Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis. <i>Sarcoma</i> , 2020 , 2020, 7192347	3.1	10
364	The immune microenvironment of uterine adenosarcomas. <i>Clinical Sarcoma Research</i> , 2020 , 10, 5	2.5	4
363	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020 , 26, 1258-1266	12.9	55
362	Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. <i>Acta Biomaterialia</i> , 2019 , 100, 38-51	10.8	14
361	MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019 , 11,	6.6	12
360	Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores. <i>Journal of Cutaneous Pathology</i> , 2019 , 46, 484-489	1.7	3
359	Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the , , and Genes: A Study of the College of American Pathologists Molecular Oncology Committee. <i>Archives of Pathology and Laboratory Medicine</i> , 2019 , 143, 1203-1211	5	8
358	Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 1167-1174	4	13
357	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019 , 35, 204-220.e9	24.3	32
356	Applications of Molecular Testing to Differential Diagnosis 2019 , 513-556		
355	Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 189-207.e11	4.5	9
354	PAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation. <i>Modern Pathology</i> , 2019 , 32, 154-156	9.8	7
353	The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. <i>Journal of Surgical Oncology</i> , 2019 , 120, 382-388	2.8	3
352	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1148-1159	21.7	148
351	Genomic Applications in Melanoma 2019 , 509-540		
350	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 728-731	4.3	5
349	B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019 , 25, 3455-3467	12.9	16
348	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019 , 9, 628-645	24.4	124

347	Extraskelatal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 238-242	2.7	4
346	Extraskelatal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 744-748	2.7	9
345	T-cell trafficking plays an essential role in tumor immunity. <i>Laboratory Investigation</i> , 2019 , 99, 85-92	5.9	7
344	Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. <i>Archives of Pathology and Laboratory Medicine</i> , 2019 , 143, 463-471	5	19
343	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 1242-1253	5	72
342	A Preexisting Rare Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in Melanoma and Is Dependent on S6K1 Signaling. <i>Cancer Discovery</i> , 2018 , 8, 556-567	24.4	42
341	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018 , 173, 400-416.e11	56.2	1072
340	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018 , 173, 371-385.e18	56.2	854
339	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018 , 173, 291-304.e6	56.2	888
338	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018 , 173, 305-320.e10	56.2	166
337	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018 , 173, 338-354.e15	56.2	560
336	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018 , 173, 321-337.e10	56.2	1124
335	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018 , 173, 355-370.e14	56.2	342
334	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018 , 23, 227-238.e3	10.6	235
333	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018 , 23, 194-212.e6	10.6	146
332	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018 , 23, 181-193.e7	10.6	366
331	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
330	Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	26

329	Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. <i>Journal of Cutaneous Pathology</i> , 2018 , 45, 563-580	1.7	18
328	Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. <i>Journal of Surgical Oncology</i> , 2018 , 117, 879-885	2.8	2
327	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 181-193	21.7	168
326	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. <i>Journal of Pathology</i> , 2018 , 244, 512-524	9.4	92
325	The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018 , 117, 1799-1805	2.8	3
324	Analysis of HSP27 and the Autophagy Marker LC3B Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1315-1323	6.1	11
323	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	24.3	377
322	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018 , 33, 721-735.e8	24.3	228
321	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
320	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018 , 20, 37	6.3	14
319	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018 , 359, 97-103	33.3	1895
318	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>OncImmunology</i> , 2018 , 7, e1385689	7.2	22
317	Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. <i>Journal of Neurosurgery</i> , 2018 , 129, 805-814	3.2	8
316	Challenges in next generation sequencing analysis of somatic mutations in transplant patients. <i>Cancer Genetics</i> , 2018 , 226-227, 17-22	2.3	1
315	TERT promoter mutations in solitary fibrous tumour. <i>Histopathology</i> , 2018 , 73, 843-851	7.3	22
314	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018 , 24, 4865-4873	12.9	43
313	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. <i>Oncotarget</i> , 2018 , 9, 19891-19899	3.3	19
312	Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing. <i>JAMA Oncology</i> , 2018 , 4, 838-841	13.4	18

311	Primary chondro-osseous melanoma (chondrosarcomatous and osteosarcomatous melanoma). <i>Journal of Cutaneous Pathology</i> , 2018 , 45, 146-150	1.7	8
310	Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. <i>Histopathology</i> , 2018 , 72, 239-247	7.3	15
309	Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	13
308	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018 , 4, 1-6	2.6	15
307	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1631-1641	2.2	448
306	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018 , 24, 1804-1808	50.5	297
305	The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 1297-1310	3.5	6
304	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018 , 24, 1649-1654	50.5	377
303	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018 , 18, 913	4.8	37
302	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. <i>Frontiers in Immunology</i> , 2018 , 9, 2102	8.4	19
301	Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. <i>Gynecologic Oncology</i> , 2018 , 151, 243-249	4.9	10
300	Role of Elevated Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 4119-4125	12.9	5
299	Nuclear E-cadherin localization and mutation of the CTNNB1 gene: a context-dependent association. <i>Modern Pathology</i> , 2018 , 31, 1553-1559	9.8	50
298	The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. <i>Cancer Cell</i> , 2018 , 33, 1128-1141.e7	24.3	100
297	Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. <i>Journal of Neurosurgery</i> , 2017 , 126, 319-329	3.2	57
296	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	409
295	Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2145-2154	3.1	41
294	Clinicopathological features and clinical outcomes associated with TP53 and BRAF mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017 , 123, 1372-1381	6.4	28

293	EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. <i>Modern Pathology</i> , 2017 , 30, 1312-1320	3.20	50
292	Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series. <i>Journal of Cutaneous Pathology</i> , 2017 , 44, 692-697	1.7	2
291	Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. <i>Oncogene</i> , 2017 , 36, 5421-5431	9.2	24
290	Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. <i>Human Pathology</i> , 2017 , 67, 1-10	3.7	169
289	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017 , 2,	6.2	82
288	The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumours. <i>Histopathology</i> , 2017 , 70, 946-953	7.3	6
287	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2017 , 18, 1493-1501	21.7	544
286	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 472-492	220.7	1044
285	A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 1679-1685	5	15
284	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Scientific Reports</i> , 2017 , 7, 11836	4.9	34
283	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017 , 30, 1433-1442	9.8	152
282	USP6 activation in nodular fasciitis by promoter-swapping gene fusions. <i>Modern Pathology</i> , 2017 , 30, 1577-1588	9.8	61
281	Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. <i>Melanoma Research</i> , 2017 , 27, 126-133	3.3	3
280	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017 , 32, 204-220.e15	24.3	391
279	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017 , 22, 1271-1277	5.7	16
278	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolmmunology</i> , 2017 , 6, e1361097	7.2	31
277	Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. <i>Cancer Biology and Therapy</i> , 2017 , 18, 816-826	4.6	11
276	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017 , 171, 950-965.e28	56.2	451

275	NF1 Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. <i>Cancer Research</i> , 2017 , 77, 4486-4497	10.1	13
274	PRKCI promotes immune suppression in ovarian cancer. <i>Genes and Development</i> , 2017 , 31, 1109-1121	12.6	43
273	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. <i>Translational Oncology</i> , 2017 , 10, 546-554	4.9	8
272	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>OncImmunity</i> , 2017 , 6, e1321187	7.2	32
271	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , 2017 , 7, 11	2.5	32
270	Molecular profiling of sarcomas: new vistas for precision medicine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 243-255	5.1	7
269	Synovial Sarcoma of the Head and Neck: A Single Institution Review. <i>Sarcoma</i> , 2017 , 2017, 2016752	3.1	17
268	Risk Models for Individualized Prognosis in the Practice of Precision Oncology 2017 , 47-52		0
267	Soft Tissue Sarcoma of the Head and Neck 2017 , 499-505		3
266	Soft Tissue Sarcoma of the Trunk and Extremities 2017 , 507-515		5
265	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs 2017 , 517-521		2
264	Gastrointestinal Stromal Tumor 2017 , 523-529		5
263	Soft Tissue Sarcoma of the Retroperitoneum 2017 , 531-537		3
262	Melanoma of the Skin 2017 , 563-586		58
261	Soft Tissue Sarcoma [Unusual Histologies and Sites] 2017 , 539-545		
260	SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. <i>Clinical Cancer Research</i> , 2016 , 22, 1150-60	12.9	62
259	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	33
258	Myxofibrosarcoma. <i>Surgical Oncology Clinics of North America</i> , 2016 , 25, 775-88	2.7	36

257	Modeling synovial sarcoma metastasis in the mouse: PI3Rlipid signaling and inflammation. <i>Journal of Experimental Medicine</i> , 2016 , 213, 2989-3005	16.6	23
256	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016 , 14, 168	11.4	87
255	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. <i>Scientific Reports</i> , 2016 , 6, 19649	4.9	10
254	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 787-92	7.3	4
253	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. <i>Laboratory Investigation</i> , 2016 , 96, 885-94	5.9	10
252	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016 , 6, 827-37	24.4	561
251	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016 , 6, 202-16	24.4	841
250	Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. <i>Cancer Biology and Therapy</i> , 2016 , 17, 129-38	4.6	8
249	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. <i>Modern Pathology</i> , 2016 , 29, 582-90	9.8	120
248	Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. <i>European Journal of Cancer</i> , 2016 , 56, 37-44	7.5	30
247	Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2220-8	3.1	18
246	MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. <i>British Journal of Radiology</i> , 2016 , 89, 20150308	3.4	12
245	Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 155-63	4.8	5
244	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016 , 53, 84-95	7.5	68
243	Expression and clinical correlations of PRAME in sarcoma subtypes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11067-11067	2.2	7
242	The PI3K-AKT Pathway in Melanoma 2016 , 165-180		3
241	Head and neck synovial sarcomas: Clinical characteristics and survival.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e22523-e22523	2.2	
240	Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (muts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9535-9535	2.2	

239	Non-Radiographic Risk Factors Differentiating Atypical Lipomatous Tumors from Lipomas. <i>Frontiers in Oncology</i> , 2016 , 6, 197	5.3	10
238	Prognosis of T1 synovial sarcoma depends upon surgery by oncologic surgeons. <i>Journal of Surgical Oncology</i> , 2016 , 114, 490-4	2.8	8
237	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 355-7	5	8
236	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. <i>JAMA Surgery</i> , 2016 , 151, 347-54	5.4	26
235	PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 1305-15	6.7	30
234	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1056-64	12.4	34
233	Cutaneous nodular fasciitis with genetic analysis: a case series. <i>Journal of Cutaneous Pathology</i> , 2016 , 43, 1143-1149	1.7	16
232	Sarcoma Brain Metastases: 28 Years of Experience at a Single Institution. <i>Annals of Surgical Oncology</i> , 2016 , 23, 962-967	3.1	5
231	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 370-4	220.7	219
230	The genomic landscape of epithelioid sarcoma cell lines and tumours. <i>Journal of Pathology</i> , 2016 , 238, 63-73	9.4	27
229	NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. <i>Oncogene</i> , 2015 , 34, 5069-79	9.2	80
228	Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 2644-51	12.9	63
227	The Cancer Genomics Resource List 2014. <i>Archives of Pathology and Laboratory Medicine</i> , 2015 , 139, 989-1008	3.008	16
226	Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. <i>Human Pathology</i> , 2015 , 46, 1015-26	3.7	16
225	Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases. <i>Clinical Sarcoma Research</i> , 2015 , 5, 7	2.5	25
224	Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. <i>Cell Cycle</i> , 2015 , 14, 2323-32	4.7	31
223	Extensive survey of STAT6 expression in a large series of mesenchymal tumors. <i>American Journal of Clinical Pathology</i> , 2015 , 143, 672-82	1.9	132
222	New, tolerable B-secretase inhibitor takes desmoid down a notch. <i>Clinical Cancer Research</i> , 2015 , 21, 7-9	12.9	16

221	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 713-21	1.9	26
220	Dual Roles of RNF2 in Melanoma Progression. <i>Cancer Discovery</i> , 2015 , 5, 1314-27	24.4	47
219	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2015 , 139, 1271-5	5	3
218	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015 , 46, 1101-10	3.7	33
217	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. <i>Modern Pathology</i> , 2015 , 28, 587-95	9.8	47
216	BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. <i>Modern Pathology</i> , 2015 , 28, 575-86	9.8	93
215	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 508-515	4.3	99
214	Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. <i>Cancer</i> , 2015 , 121, 4088-96	6.4	38
213	Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. <i>BMC Cancer</i> , 2015 , 15, 886	4.8	15
212	AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. <i>BMC Cancer</i> , 2015 , 15, 901	4.8	15
211	Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 1701-7	6.7	3
210	Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. <i>Cancer</i> , 2015 , 121, 3659-67	6.4	13
209	Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. <i>Journal of Cutaneous Pathology</i> , 2015 , 42, 308-17	1.7	11
208	Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. <i>Histopathology</i> , 2015 , 67, 699-708	7.3	46
207	Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. <i>Molecular Cancer</i> , 2015 , 14, 55	42.1	28
206	Raman spectroscopy complements optical coherent tomography in tissue classification and cancer detection 2015 ,		1
205	Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. <i>Histopathology</i> , 2015 , 66, 627-38	7.3	19
204	The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. <i>Laboratory Investigation</i> , 2015 , 95, 951-61	5.9	9

203	Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. <i>Journal of Clinical Investigation</i> , 2015 , 125, 2965-78	15.9	21
202	A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9071-9071	2.2	1
201	Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20051-e20051	2.2	1
200	Application of Molecular Pathology to Cutaneous Melanocytic Lesions. <i>Molecular Pathology Library</i> , 2015 , 103-124		
199	Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9064-9064	2.2	
198	Clinical Characteristics and Treatment Outcomes of Clear Cell Chondrosarcomas: MD Anderson Cancer Center Series.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10531-10531	2.2	
197	A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9039-9039	2.2	
196	Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9057-9057	2.2	
195	Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10550-10550 ²	2.2	
194	Impact of surgical resection for subdiaphragmatic paragangliomas. <i>World Journal of Surgery</i> , 2014 , 38, 733-41	3.3	3
193	EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. <i>Journal of Pathology</i> , 2014 , 232, 308-18	9.4	47
192	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. <i>Nature Genetics</i> , 2014 , 46, 376-379	36.3	196
191	Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. <i>Clinical Cancer Research</i> , 2014 , 20, 5537-46	12.9	115
190	Mesenchymal to epithelial transition in sarcomas. <i>European Journal of Cancer</i> , 2014 , 50, 593-601	7.5	40
189	Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. <i>Clinical Cancer Research</i> , 2014 , 20, 5527-36	12.9	103
188	Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. <i>Annals of Surgical Oncology</i> , 2014 , 21, 2499-505	3.1	26
187	Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?. <i>Annals of Surgical Oncology</i> , 2014 , 21, 2136-43	3.1	67
186	ERG and FLI1 protein expression in epithelioid sarcoma. <i>Modern Pathology</i> , 2014 , 27, 496-501	9.8	59

185	Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma. <i>BMC Clinical Pathology</i> , 2014 , 14, 42	3	8
184	Targeted therapies for sarcomas: new roles for the pathologist. <i>Histopathology</i> , 2014 , 64, 119-33	7.3	12
183	Line-scan Raman microscopy complements optical coherence tomography for tumor boundary detection. <i>Laser Physics Letters</i> , 2014 , 11, 105602	1.5	17
182	Differential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas. <i>Biomarkers in Cancer</i> , 2014 , 6, 1-10	7	3
181	Three-dimensional computational analysis of optical coherence tomography images for the detection of soft tissue sarcomas. <i>Journal of Biomedical Optics</i> , 2014 , 19, 21102	3.5	22
180	Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10512-10512	2.2	1
179	Synovial sarcoma: Evaluation of response to treatment with gemcitabin and docetaxel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10564-10564	2.2	2
178	Clinical characteristics of patients with non-V600 BRAF mutant melanomas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9100-9100	2.2	4
177	Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. <i>Oncotarget</i> , 2014 , 5, 9065-78	3.3	15
176	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation positive melanoma with metastases to the brain (BRV116521).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9112-TPS9112	2.2	
175	Phase I study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10571-10571	2.2	
174	The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. <i>Clinical Sarcoma Research</i> , 2013 , 3, 7	2.5	62
173	Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013 , 119, 3821-9	6.4	79
172	Computational analysis of optical coherence tomography images for the detection of soft tissue sarcomas 2013 ,		2
171	Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution experience. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2364-72	3.1	50
170	Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. <i>Journal of Molecular Diagnostics</i> , 2013 , 15, 220-6	5.1	157
169	R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations. <i>American Journal of Pathology</i> , 2013 , 182, 1494-500	5.8	45
168	Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. <i>Stem Cell Research</i> , 2013 , 11, 772-81	1.6	15

167	CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. <i>Cell</i> , 2013 , 152, 1077-90	56.2	113
166	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. <i>Thyroid</i> , 2013 , 23, 1277-83	6.2	154
165	Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. <i>Annals of Surgical Oncology</i> , 2013 , 20, 1267-74	3.1	87
164	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013 , 119, 799-805	6.4	59
163	Angiosarcoma: a tissue microarray study with diagnostic implications. <i>American Journal of Dermatopathology</i> , 2013 , 35, 432-7	0.9	47
162	Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6500-5	11.5	180
161	Pleomorphic fibroma and dermal atypical lipomatous tumor: are they related?. <i>Journal of Cutaneous Pathology</i> , 2013 , 40, 379-84	1.7	9
160	Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2013 , 40, 730-3	1.7	7
159	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. <i>Cancer</i> , 2013 , 119, 3696-702	6.4	122
158	Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. <i>Cancer</i> , 2013 , 119, 1868-77	6.4	74
157	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2013 , 109, 1085-92	8.7	50
156	Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles. <i>Molecular Cancer Research</i> , 2013 , 11, 557-67	6.6	16
155	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. <i>PLoS ONE</i> , 2013 , 8, e67306	3.7	79
154	Orthopedic Oncologic Surgical Specimen Management and Surgical Pathology 2013 , 43-74		1
153	Expression of ERG, an Ets family transcription factor, distinguishes cutaneous angiosarcoma from histological mimics. <i>Histopathology</i> , 2012 , 61, 989-91	7.3	43
152	Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. <i>Journal of Cutaneous Pathology</i> , 2012 , 39, 493-9	1.7	36
151	BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. <i>Journal of Cutaneous Pathology</i> , 2012 , 39, 821-5	1.7	21
150	PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 213-20	4.9	17

149	MiR-155 is a liposarcoma oncogene that targets casein kinase-1 β and enhances E-catenin signaling. <i>Cancer Research</i> , 2012 , 72, 1751-62	10.1	88
148	New strategies in melanoma: molecular testing in advanced disease. <i>Clinical Cancer Research</i> , 2012 , 18, 1195-200	12.9	44
147	Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1758-69	6.1	36
146	Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. <i>Cancer Research</i> , 2012 , 72, 4724-32	10.1	34
145	CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm. <i>Pediatric and Developmental Pathology</i> , 2012 , 15, 361-7	2.2	33
144	Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. <i>Modern Pathology</i> , 2012 , 25, 1298-306	9.8	294
143	Noncontact measurement of elasticity for the detection of soft-tissue tumors using phase-sensitive optical coherence tomography combined with a focused air-puff system. <i>Optics Letters</i> , 2012 , 37, 5184-6 ³		67
142	Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. <i>Clinical Sarcoma Research</i> , 2012 , 2, 25	2.5	18
141	Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. <i>Clinical Sarcoma Research</i> , 2012 , 2, 2	2.5	41
140	ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. <i>Journal of Pathology</i> , 2012 , 227, 223-33	9.4	64
139	Sarcoma metastases to the skin: a clinicopathologic study of 65 patients. <i>Cancer</i> , 2012 , 118, 2900-4	6.4	30
138	NRAS mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012 , 118, 4014-23	6.4	483
137	Exploiting antitumor immunity to overcome relapse and improve remission duration. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1113-24	7.4	28
136	Pseudocystic dermatofibrosarcoma protuberans: report of two cases and demonstration of COL1A1-PDGFB rearrangement. <i>Journal of Cutaneous Pathology</i> , 2012 , 39, 356-60	1.7	1
135	Pathology of gastrointestinal stromal tumors. <i>Clinical Medicine Insights Pathology</i> , 2012 , 5, 23-33		32
134	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. <i>Annals of Oncology</i> , 2012 , 23, 1335-1340	10.3	41
133	FUS rearrangements are rare in pure sclerosing epithelioid fibrosarcoma. <i>Modern Pathology</i> , 2012 , 25, 846-53	9.8	55
132	Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. <i>Modern Pathology</i> , 2012 , 25, 212-21	9.8	67

131	Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. <i>Modern Pathology</i> , 2012 , 25, 1378-83	9.8	82
130	RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. <i>Cellular Physiology and Biochemistry</i> , 2012 , 29, 361-72	3.9	22
129	Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2012 , 18, 4633-45	12.9	40
128	INK4a/ARF [corrected] inactivation with activation of the NF- κ B/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. <i>Cancer Research</i> , 2012 , 72, 4682-95	10.1	30
127	Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 1120-8	12.9	42
126	Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 2545-57	12.9	36
125	New therapeutic targets in soft tissue sarcoma. <i>Advances in Anatomic Pathology</i> , 2012 , 19, 170-80	5.1	43
124	p53 staining correlates with tumor type and location in sebaceous neoplasms. <i>American Journal of Dermatopathology</i> , 2012 , 34, 129-35; quiz 136-8	0.9	37
123	MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 1444-51	6.7	176
122	Lymphocyte composition and distribution in inflammatory, well-differentiated retroperitoneal liposarcoma: clues to a potential adaptive immune response and therapeutic implications. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 941-4	6.7	20
121	Cutaneous digital papillary adenocarcinoma: a clinicopathologic study of 31 cases of a rare neoplasm with new observations. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 1883-91	6.7	67
120	Tumors of the surface epithelium 2012 , 1076-1149		10
119	Tumors of the hair follicle 2012 , 1445-1487		3
118	Tumors of the sweat glands 2012 , 1508-1570		6
117	Connective tissue tumors 2012 , 1588-1768		3
116	Pathology of Desmoid Tumors 2012 , 17-28		
115	FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. <i>Histology and Histopathology</i> , 2012 , 27, 641-9	1.4	22
114	Nevoid melanoma. <i>Clinics in Laboratory Medicine</i> , 2011 , 31, 243-53	2.1	25

113	New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. <i>Drug Resistance Updates</i> , 2011 , 14, 52-66	23.2	40
112	Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. <i>Science Translational Medicine</i> , 2011 , 3, 98ra82	17.5	252
111	Desmoid tumor: current multidisciplinary approaches. <i>Annals of Plastic Surgery</i> , 2011 , 67, 551-64	1.7	30
110	Dermatofibrosarcoma protuberans with unusual sarcomatous transformation: a series of 4 cases with molecular confirmation. <i>American Journal of Dermatopathology</i> , 2011 , 33, 354-60	0.9	24
109	Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 135-44	6.7	227
108	Expression of drugable tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. <i>Histopathology</i> , 2011 , 59, 156-9	7.3	9
107	The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. <i>Histopathology</i> , 2011 , 59, 556-61	7.3	21
106	T-cell-rich angiomatoid polypoid pseudolymphoma of the skin: a clinicopathologic study of 17 cases and a proposed nomenclature. <i>Journal of Cutaneous Pathology</i> , 2011 , 38, 475-82	1.7	19
105	Analysis of α integrin protein expression in human eyelid and periorbital squamous cell carcinomas. <i>Journal of Cutaneous Pathology</i> , 2011 , 38, 570-5	1.7	3
104	An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. <i>Laboratory Investigation</i> , 2011 , 91, 392-403	5.9	58
103	Clinicopathologic considerations: how can we fine tune our approach to sarcoma?. <i>Seminars in Oncology</i> , 2011 , 38 Suppl 3, S3-18	5.5	45
102	Difficult to diagnose desmoid tumours: a potential role for CTNNB1 mutational analysis. <i>Histopathology</i> , 2011 , 59, 336-40	7.3	31
101	Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3762-70	3.1	47
100	Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67 Suppl 1, S15-24	3.5	50
99	Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. <i>Journal of Pathology</i> , 2011 , 225, 574-82	9.4	17
98	Liposarcoma in children and young adults: a multi-institutional experience. <i>Pediatric Blood and Cancer</i> , 2011 , 57, 1142-6	3	49
97	High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 849-58	5	42
96	Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. <i>Cancer</i> , 2011 , 117, 380-9	6.4	32

95	Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. <i>Cancer</i> , 2011 , 117, 4939-47	6.4	166
94	Pleomorphic liposarcoma: clinical observations and molecular variables. <i>Cancer</i> , 2011 , 117, 5359-69	6.4	68
93	Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. <i>Oncologist</i> , 2011 , 16, 512-22	5.7	42
92	Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 3943-55	12.9	71
91	Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. <i>Clinical Cancer Research</i> , 2011 , 17, 5901-12	12.9	32
90	Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. <i>Cancer Research</i> , 2011 , 71, 185-96	10.1	73
89	Revealing retroperitoneal liposarcoma morphology using optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2011 , 16, 020502	3.5	14
88	Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. <i>Journal of Clinical Investigation</i> , 2011 , 121, 174-83	15.9	87
87	The molecular pathology of sarcomas. <i>Cancer Biomarkers</i> , 2010 , 9, 475-91	3.8	10
86	Epidermal growth factor receptor (EGFR) expression in periorbital and extraocular sebaceous carcinoma. <i>Journal of Cutaneous Pathology</i> , 2010 , 37, 231-6	1.7	18
85	Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. <i>Histopathology</i> , 2010 , 56, 133-47	7.3	98
84	Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. <i>Annals of Oncology</i> , 2010 , 21, 1112-20	10.3	17
83	Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?. <i>Modern Pathology</i> , 2010 , 23, 1301-6	9.8	83
82	TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. <i>Clinical Cancer Research</i> , 2010 , 16, 2591-604	12.9	51
81	Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 14333-8	11.5	165
80	Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. <i>PLoS ONE</i> , 2010 , 5, e10105	3.7	152
79	Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1772-9	2.2	297
78	Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. <i>Molecular and Cellular Proteomics</i> , 2010 , 9, 2405-13	7.6	48

77	Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. <i>Modern Pathology</i> , 2010 , 23, 567-73	9.8	130
76	Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. <i>Modern Pathology</i> , 2010 , 23, 1307-15	9.8	52
75	Angiosarcoma: clinical and molecular insights. <i>Annals of Surgery</i> , 2010 , 251, 1098-106	7.8	143
74	Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 216-22	6.7	132
73	COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin. <i>American Journal of Dermatopathology</i> , 2010 , 32, 149-53	0.9	10
72	Primary vascular tumors and tumor-like lesions of the kidney: a clinicopathologic analysis of 25 cases. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 942-9	6.7	93
71	Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. <i>Journal of Surgical Oncology</i> , 2010 , 101, 327-33	2.8	26
70	Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2079-85	6.1	163
69	Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. <i>Clinical Cancer Research</i> , 2009 , 15, 2637-46	12.9	13
68	Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. <i>Expert Reviews in Molecular Medicine</i> , 2009 , 11, e30	6.7	72
67	IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. <i>Cancer Research</i> , 2009 , 69, 1080-8	10.1	29
66	Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1157-68	6.1	80
65	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 7538-7546	12.9	184
64	Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. <i>Cancer</i> , 2009 , 115, 2971-9	6.4	22
63	Ewing's sarcoma: standard and experimental treatment options. <i>Current Treatment Options in Oncology</i> , 2009 , 10, 126-40	5.4	107
62	Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. <i>Histopathology</i> , 2009 , 55, 750-5	7.3	29
61	Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. <i>Modern Pathology</i> , 2009 , 22, 66-70	9.8	58
60	Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. <i>Modern Pathology</i> , 2009 , 22, 1446-56	9.8	173

59	Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). <i>Modern Pathology</i> , 2009 , 22, 1201-9	9.8	156
58	A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. <i>Annals of Surgical Oncology</i> , 2009 , 16, 910-9	3.1	138
57	Outcome of locally recurrent and metastatic angiosarcoma. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2502-9	3.1	48
56	Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2579-86	3.1	51
55	Contemporary pathology of gastrointestinal stromal tumors. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 49-68, vii-viii	3.1	30
54	Nevoid Melanoma. <i>Surgical Pathology Clinics</i> , 2009 , 2, 521-33	3.9	2
53	Desmoid tumor: from surgical extirpation to molecular dissection. <i>Current Opinion in Oncology</i> , 2009 , 21, 352-9	4.2	44
52	Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: a series of 5 cases with molecular analysis. <i>American Journal of Dermatopathology</i> , 2009 , 31, 297-300	0.9	16
51	The skin allograft revisited: a potentially permanent wound coverage option in the critically ill patient. <i>Plastic and Reconstructive Surgery</i> , 2009 , 123, 1755-1758	2.7	17
50	Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. <i>Annals of Surgery</i> , 2009 , 249, 1014-22	7.8	200
49	Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. <i>PLoS ONE</i> , 2009 , 4, e8075	3.7	54
48	Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. <i>Modern Pathology</i> , 2008 , 21, 1121-9	9.8	29
47	Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma. <i>Modern Pathology</i> , 2008 , 21, 1303-10	9.8	37
46	Metastatic basal cell carcinoma exhibits reduced actin expression. <i>Modern Pathology</i> , 2008 , 21, 540-3	9.8	30
45	Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. <i>Molecular Oncology</i> , 2008 , 2, 161-3	7.9	16
44	Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. <i>Human Pathology</i> , 2008 , 39, 184-93	3.7	186
43	Cellular blue nevi of the eyelid: A possible diagnostic pitfall. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 257-60	4.5	13
42	Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. <i>American Journal of Pathology</i> , 2008 , 173, 1518-27	5.8	336

41	Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. <i>Clinical Cancer Research</i> , 2008 , 14, 5466-75	12.9	28
40	Sarcoma epidemiology and etiology: potential environmental and genetic factors. <i>Surgical Clinics of North America</i> , 2008 , 88, 451-81, v	4	97
39	Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. <i>Clinical Cancer Research</i> , 2008 , 14, 5033-42	12.9	33
38	Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 737-40		103
37	Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , 2008 , 14, 2785-95	12.9	32
36	Uterine tumors with neuroectodermal differentiation: a series of 17 cases and review of the literature. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 219-28	6.7	63
35	Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 936-42	6.7	83
34	Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 682-90	6.7	105
33	Genetic aberrations of gastrointestinal stromal tumors. <i>Cancer</i> , 2008 , 113, 1532-43	6.4	58
32	Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. <i>International Journal of Cancer</i> , 2008 , 122, 711-8	7.5	62
31	New perspectives for staging and prognosis in soft tissue sarcoma. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2739-48	3.1	105
30	Dermatofibrosarcoma protuberans and giant cell fibroblastoma exhibit CD99 positivity. <i>Journal of Cutaneous Pathology</i> , 2008 , 35, 647-50	1.7	16
29	High prevalence of p53 exon 4 mutations in soft tissue sarcoma. <i>Cancer</i> , 2007 , 109, 2323-33	6.4	33
28	Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. <i>EMBO Reports</i> , 2007 , 8, 497-503	6.5	167
27	Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. <i>Journal of Cutaneous Pathology</i> , 2007 , 34, 49-54	1.7	76
26	Renal cell carcinoma marker (RCC-Ma) is specific for cutaneous metastasis of renal cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2007 , 34, 381-5	1.7	24
25	Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. <i>Journal of Cutaneous Pathology</i> , 2007 , 34, 474-80	1.7	104
24	Sarcoma molecular testing: diagnosis and prognosis. <i>Current Oncology Reports</i> , 2007 , 9, 309-15	6.3	15

23	Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. <i>Clinical Cancer Research</i> , 2007 , 13, 7314-21	12.9	72
22	Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. <i>Clinical Cancer Research</i> , 2007 , 13, 6727-34	12.9	36
21	Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1650-60	6.1	101
20	Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients. <i>American Journal of Dermatopathology</i> , 2007 , 29, 62-7	0.9	12
19	Metastasizing adenocarcinoma and multiple neoplastic proliferations arising in a nevus sebaceus. <i>American Journal of Dermatopathology</i> , 2007 , 29, 462-6	0.9	30
18	Merkel cell tumor in a trichilemmal cyst: collision or association?. <i>American Journal of Dermatopathology</i> , 2007 , 29, 180-3	0.9	21
17	Epidermodysplasia verruciformis in the setting of graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, S78-80	4.5	19
16	Nephrogenic fibrosing dermopathy with recurrence after allograft failure. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, S109-11	4.5	17
15	Staging soft tissue sarcoma: evolution and change. <i>Ca-A Cancer Journal for Clinicians</i> , 2006 , 56, 282-91; quiz 314-5	220.7	86
14	Genetic alterations in signaling pathways in melanoma. <i>Clinical Cancer Research</i> , 2006 , 12, 2301s-2307s	12.9	139
13	A keratinocyte hypermotility/growth-arrest response involving laminin 5 and p16INK4A activated in wound healing and senescence. <i>American Journal of Pathology</i> , 2006 , 168, 1821-37	5.8	57
12	Human sebaceous tumors harbor inactivating mutations in LEF1. <i>Nature Medicine</i> , 2006 , 12, 395-7	50.5	132
11	Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 154-60	4.3	282
10	Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6709-15	12.9	79
9	Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2006 , 130, 1199-207	5	79
8	Primitive nonneural granular cell tumors of skin: clinicopathologic analysis of 13 cases. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 927-34	6.7	86
7	Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. <i>Journal of Cutaneous Pathology</i> , 2005 , 32, 148-57	1.7	96
6	Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin. <i>Journal of Cutaneous Pathology</i> , 2005 , 32, 245-50	1.7	30

5	Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). <i>Development (Cambridge)</i> , 2005 , 132, 415-27	6.6	75
4	Distinctive dermal clear cell mesenchymal neoplasm: clinicopathologic analysis of five cases. <i>American Journal of Dermatopathology</i> , 2004 , 26, 273-9	0.9	40
3	Cell-of-Origin Analysis of Metastatic Gastric Cancer Uncovers the Origin of Inherent Intratumor Heterogeneity and a Fundamental Prognostic Signature		1
2	New cellular models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor		1
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> ,	10.7	49